| Identification | |
| Name: | L-Tyrosine,O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, sodium salt (1:1) |
| Synonyms: | L-Tyrosine,O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, monosodium salt (9CI);Thyroxine,monosodium salt, L- (8CI);Berlthyrox;Dathroid;Droxine;Eferox;Elthyrone;Elthyroxine;Eltroxin;Euthyrox;Eutirox;L-Thyroxin Henning;L-Thyroxinemonosodium salt;L-Thyroxine sodium;L-Thyroxine sodium salt;Laevoxin;Letrox;Letter;Levaxin;Leventa;Levo-T;Levoroxine;Levothroid;Levothyrox;Levothyroxine sodium;Levotirox;Levotiroxina;Levoxyl;Monosodium thyroxine;NSC 259940;Oroxine;Puran T 4;Sodium L-thyroxine;Sodium levothyroxine;Sodium thyroxin;Sodium thyroxinate;Sodium thyroxine;Synthroid;Synthroidsodium;Synthrox;T 4KP;T4 Montpellier 100;Thevier;Throxinique;Thyradin;Thyradin S;Thyrax Duotab;Thyrex;Thyro 4;Thyrosit;Thyroxevan;Thyroxinesodium;Thyroxine sodium salt;Tiroidine; |
| CAS: | 55-03-8 |
| EINECS: | 200-221-4 |
| Molecular Formula: | C15H10I4NNaO4 |
| Molecular Weight: | 776.87002 |
| InChI: | InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23) |
| Molecular Structure: |  |
| Properties | |
| Transport: | 2811 |
| Melting Point: | 207-210 (dec.)(lit.) |
| Density: | g/cm3 |
| Water Solubility: | cell culture medium: 0.1 mg/mL in water |
| Solubility: | cell culture medium: 0.1 mg/mL in water |
| Specification: |
Levothyroxine sodium (55-03-8) is a synthetic form of thyroxine (thyroid hormone). The natural hormone is chemically in the L-form, as is the pharmaceutical agent. Dextrothyroxine (D-thyroxine) briefly saw research as an anticholesterol agent but was pulled due to cardiac side-effects.This medicine is a hormone replacement usually given to patients with thyroid problems, specifically, hypothyroidism.It also has been given to people who have goitre or an enlarged thyroid gland.Synthetic levothyroxine can cause adverse effects such as palpitations, nervousness, headache, insomnia, swelling of the legs and ankles, weight loss, and increased appetite. Allergic reactions to the drug are characterized by symptoms such as difficulty breathing, shortness of breath, or swelling of the face and tongue.Acute overdose may cause fever, hypoglycemia, heart failure, coma and unrecognized adrenal insufficiency. Acute massive overdose may be life-threatening ; treatment should be symptomatic and supportive. Massive overdose may require beta-blockers for increased sympathomimetic activity.and the side effects of overdosing appear 6 hours to 11 days after ingestion.It is the most prescribed brand of T4 in the United States. Synthroid was marketed in 1955, but was not FDA approved at that time as it was "generally regarded safe".In the 1990s, in response to debate as to whether Synthroid was more effective than other levothyroxine preparations, (which ended up concluding that there was little difference between Synthroid and generic brands) all levothyroxine preparations were required to undergo the formal FDA approval process. Synthroid was approved by the FDA on 24 July 2002.The EU has recently standardized the use of the International Nonproprietary Name "levothyroxine" for the drug. Common brand names include Thyrax, Euthyrox, Levaxin, L-thyroxine and Eltroxin in Europe ; Thyrox in South Asia ; Eutirox, Levoxyl and Synthroid in North America. There are also numerous generic versions. |
| Report: |
Reported in EPA TSCA Inventory. |
| Packinggroup: | II |
| Storage Temperature: | 2-8°C |
| Color: | CRYSTALS NEEDLES |
| Usage: | One of the thyroid hormones involved in the maintenance of metabolic homeostasis. Synthesized and stored as amino acid residues of thyroglobulin, the major protein component of the thyroid follicular colloid. Synthesis and secretion are regulated by the pituitary hormone (TSH). Deiodinated in peripheral tissues to the active metabolite, liothyronine. The D-form has very little activity as a thyroid hormone, but has been used to treat hyperlipidemia. |
| Safety Data | |
 |
|
